**Section: Contact Information**

First Name: Lindsay  
Last Name: Morton  
Institution: National Cancer Institute, Division of Cancer Epidemiology and Genetics  
Address 1: 9609 Medical Center Drive, Rom 7E-454  
Address 2:  
City: Bethesda  
State/Province/Region: MD  
Country: US  
Zip/Postal Code: 20892  
Phone Number: 2402767377  
Alternate Phone Number:  
Email Address: mortonli@mail.nih.gov

**Section: Project Requirements and Description**

**Group: Requirements to submit AOI**

A comprehensive review of previously published data has been completed. : Yes

The specific aims are clear and focused. : Yes

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : Yes

Project Title: Genetic Susceptibility to Certain Subsequent Neoplasms after Radiotherapy for Childhood Cancer

Planned research population (eligibility criteria):  
CCSS expansion cohort members with WGS data

Proposed specific aims:

To leverage the whole genome sequencing data in the CCSS Expansion Cohort to augment ongoing analyses in the CCSS Original Cohort to identify rare coding variants and genome-wide common variants that are associated with risk for developing subsequent neoplasms in three key categories:

1. Radiation-related subsequent neoplasms (as a group, no primary discovery in a specific type)
2. Breast cancer
3. Thyroid cancer

Will the project require non-CCSS funding to complete? : Yes

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:  
The analysis will be fully supported by the Intramural Research Program of the National Cancer Institute.

**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information : No  
Biological samples : No  
Medical record data : No  
If yes to any of the above, please briefly describe.:  

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**

- Second Malignancy: Secondary
- Chronic Disease:
- Psychology / Neuropsychology:
- Genetics: Primary
- Cancer Control:
- Epidemiology / Biostatistics:

**Section: Outcomes or Correlative Factors**

- Late mortality:
- Second Malignancy: Primary

**Group: Health Behaviors**

- Tobacco:
- Alcohol:
- Physical activity:
- Medical screening:
- Other:
  If other, please specify:

**Group: Psychosocial**

- Insurance:
- Marriage:
- Education:
- Employment:
- Other:
  If other, please specify:

**Group: Medical Conditions**

- Hearing/Vision/Speech:
- Hormonal systems:
- Heart and vascular:
- Respiratory:
- Digestive:
- Surgical procedures:
- Brain and nervous system:
- Other:
  If other, please specify:

**Group: Medications**

Describe medications:

**Group: Psychologic/Quality of Life**

- BSI-18:
- SF-36:
- CCSS-NCQ:
- PTS:
PTG:
Other:
If other, please specify:

**Group: Other**
Pregnancy and offspring:
Family history:
Chronic conditions (CTCAE v3):
Health status:

**Group: Demographic**
Age:
Race:
Sex:
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: *Correlative Factors*
Radiation therapy: *Correlative Factors*
Surgery:

**Section: Anticipated Sources of Statistical Support**
CCSS Statistical Center:
Local institutional statistician: *Yes*
If local, please provide the name(s) and contact information of the statistician(s) to be involved.
**Joshua Sampson, PhD**
Will this project utilize CCSS biologic samples?: *Yes*
If yes, which of the following?: *Buccal cell DNA, Peripheral blood*
If other, please explain:

**Section: Other General Comments**
Other General Comments:
1. Analyses will consider all childhood cancer survivors as well as stratifying the population by radiation dose to the site of the subsequent neoplasm. Radiation dose will be estimated using body-region dosimetry. Cytotoxic chemotherapy exposure will be adjusted for in the models.

2. Pending discussions with and agreement from all involved PIs, data may be combined with additional studies to maximize power for discovery and evaluate consistency of results in independent populations, e.g., an NCI collaboration with a case-control study of breast cancer after Hodgkin lymphoma, an NCI-led study of breast cancer in patients with Li Fraumeni Syndrome, and an NCI-led study of thyroid cancer after the Chernobyl accident.

I agree to share this information with St. Jude: *Yes*